The Journal of clinical endocrinology and metabolism
The most recent articles from:
March 2017
-
J. Clin. Endocrinol. Metab. · Mar 2017
Randomized Controlled Trial Multicenter StudyPioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
Pioglitazone reduces cardiovascular risk in nondiabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture. ⋯ Fractures affected 8.8% of placebo-treated patients within 5 years after an ischemic stroke or TIA. Pioglitazone increased the absolute fracture risk by 1.6% to 4.9% and the relative risk by 47% to 60%, depending on fracture classification. Our analysis suggests that treatments to improve bone health and prevent falls may help optimize the risk/benefit ratio for pioglitazone.